Eli Lilly and Company (NYSE:LLY) is Argus Investors Counsel Inc.’s 6th Largest Position

Argus Investors Counsel Inc. decreased its holdings in Eli Lilly and Company (NYSE:LLYFree Report) by 12.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,837 shares of the company’s stock after selling 931 shares during the quarter. Eli Lilly and Company comprises approximately 2.6% of Argus Investors Counsel Inc.’s portfolio, making the stock its 6th biggest holding. Argus Investors Counsel Inc.’s holdings in Eli Lilly and Company were worth $3,986,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Thompson Investment Management Inc. purchased a new position in shares of Eli Lilly and Company in the third quarter valued at $27,000. Retirement Group LLC increased its position in shares of Eli Lilly and Company by 159.1% in the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after buying an additional 35 shares in the last quarter. Legacy Financial Group LLC purchased a new position in shares of Eli Lilly and Company in the third quarter valued at $35,000. Optiver Holding B.V. purchased a new position in shares of Eli Lilly and Company in the third quarter valued at $36,000. Finally, Cornerstone Planning Group LLC purchased a new position in shares of Eli Lilly and Company in the second quarter valued at $33,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $777.96 on Monday. The company has a market cap of $739.19 billion, a P/E ratio of 134.13, a PEG ratio of 1.71 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. Eli Lilly and Company has a one year low of $334.58 and a one year high of $800.78. The business’s 50-day simple moving average is $737.05 and its 200 day simple moving average is $639.53.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company’s revenue was up 28.1% on a year-over-year basis. During the same period last year, the business posted $2.09 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 12.42 earnings per share for the current fiscal year.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 14,388 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $630.28, for a total transaction of $9,068,468.64. Following the sale, the insider now directly owns 99,754,422 shares in the company, valued at approximately $62,873,217,098.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders have sold 195,055 shares of company stock worth $125,254,657. 0.13% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of recent research reports. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Wells Fargo & Company lifted their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. BMO Capital Markets lifted their price objective on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Truist Financial reiterated a “buy” rating and set a $850.00 price objective on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Finally, DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a research report on Wednesday, February 21st. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $689.52.

View Our Latest Stock Analysis on LLY

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.